Hedgehog (Hh) and TGF-β family members are involved in numerous overlapping processes during embryonic development, hair cycle and cancer. Herein, we demonstrate that TGF-β induces the expression of the Hh signaling molecules Gli1 and Gli2 in various human cell types, including normal fibroblasts and keratinocytes, as well as various cancer cell lines. Gli2 induction by TGF-β is rapid, independent from Hh receptor signaling, and requires a functional Smad pathway. Gli1 expression is subsequently activated in a Gli2-dependent manner. In transgenic mice overexpressing TGF-β1 in the skin, Gli1 and Gli2 expression is also elevated, and depends on Smad3. In pancreatic adenocarcinoma cell lines resistant to Hh inhibition, pharmacologic blockade of TGF-β signaling leads to repression of cell proliferation accompanied with a reduction in Gli2 expression. We thus identify TGF-β as a potent transcriptional inducer of Gli transcription factors. Targeting the cooperation of Hh and TGF-β signaling may provide new therapeutic opportunities for cancer treatment.
Introduction
The Hedgehog (Hh) signaling pathway is critical for stem cell maintenance, embryonic patterning and growth in both invertebrates and vertebrates (1) . Deregulation of the Hh pathway is a characteristic trait of a number of pathological states, including developmental syndromes with high proneness to cancer (1, 2) . Cellular responses to the Hh signal are Drosophila, and three closely related Gli proteins in vertebrates: Gli1, Gli2 and Gli3 (4) . Gli2 is thought to function upstream of Gli1 and to be the primary mediator of Hh signaling (5) , inducing Gli1 expression via direct binding to its promoter region (6) . Gli transcription factors regulate multiple cellular functions associated with malignant transformation, such as cell cycle progression and apoptosis (4, 7) .
The importance of the Hh signaling pathway in tumorigenesis was established through the discovery of inactivating mutations in the Ptch gene in patients with familial (Gorlin's syndrome) basal cell carcinomas (BCC) and sporadic BCC (8, 9) . Other tumors exhibit inappropriate Hh pathway activation. For example, some esophageal squamous cell sarcomas and transitional cell carcinomas of the bladder may carry loss-of-function mutations of the Ptch gene (10) , while gain-of-function mutations of Smo have been identified in a subset of small cell lung carcinoma (11) . Additionally, overexpression of the main Hh member Sonic hedgehog (Shh), leading to activation of Smo, has been identified in some gastro-intestinal cancers (12) and pancreatic adenocarcinomas (13) .
Similar to Hh members, Transforming Growth Factor-β (TGF-β) has emerged as a family of growth factors involved in various essential physiological processes that include embryonic development, tissue repair, cell growth control and differentiation. TGF-β isoforms are expressed in a variety of tumor types, and contribute to the aggressiveness and progression of neoplasms (14, 15) . TGF-β members signal via membrane-bound heteromeric serinethreonine kinase receptor complexes. In most cell types, TGF-β binds to TβRII in combination with TβRI, also known as ALK-5 (16) . Receptor activation by TGF-β leads to phosphorylation of cytoplasmic proteins of the Smad family. Receptor-associated Smads, Smad2 and Smad3 then heteromerize with Smad4, translocate into the nucleus, and act as transcription factors to regulate target gene expression. Smad3 is thought to contribute most Smad-dependent responses to TGF-β in the adult, while Smad2 is critical during embryogenesis (17, 18) .
In this study, we have examined the capacity of TGF-β to modulate the expression of the Hh signaling molecules Gli1 and Gli2. We provide definitive evidence, both in vitro and in vivo, for Smad-dependent activation of Gli2 expression, and consequently, that of Gli1, thereby identifying TGF-β as a cytokine ubiquitously capable of activating, enhancing, or prolonging Hh signals. Also, we demonstrate that some cyclopamine-resistant pancreatic adenocarcinoma cell lines are growth inhibited by a small molecule inhibitor of TGF-β signaling. Western analysis of total Gli2 production in dermal fibroblasts showed undetectable expression levels in unstimulated cultures. Gli2 protein became detectable 6h after addition of TGF-β, and accumulated over the 48h of incubation ( Fig. 1D ). Given the high levels of Gli2 protein detected at the 48h time-point, it is possible that TGF-β may stabilize GLI2 protein, in addition to increasing gene expression.
Materials and Methods
Of note, Gli3 (see multiplex PCR panels), Ptch, and Smo (not shown) expression in response to TGF-β showed minimal variation. (26, 27) . As a first approach to discriminate between all pathways, we tested the effects of pharmacologic inhibitors that specifically target the MAPK and PI3K pathways in parallel to a TβRI/ALK5 inhibitor on TGF-β-induced Gli2 expression.
Activation of Gli expression by TGF-β β β β does not involve the Ptch/Smo axis:
As shown in Fig. 3B , neither the MAPK inhibitors SB203580, PD98059, and SP600125, nor the PI3K inhibitor LY294002, which all effectively blocked their respective target pathway in these experiments (not shown), affected TGF-β effect on Gli2 expression, while the TβRI/ALK5 inhibitor SB431542 fully abrogated the induction.
Next, we used the breast carcinoma cell line MDA-MB-468, which carries a large homozygous deletion within chromosome 18 encompassing the entire Smad4 gene (28), and exhibits deficient Smad-dependent transcription in response to TGF-β (19, 20) . Gli2 expression in mock-transfected cells was barely detectable and was not elevated in response to TGF-β (Fig. 3C, lane 2 vs. lane 1) . However, with Smad3/4 complementation, Gli2 Genetic approaches have demonstrated that Gli2 plays the preeminent role in the transcriptional response to Hh signaling, and is required for induction of Gli1 (5, 29) . Since
Gli2 induction by TGF-β precedes that of Gli1, we hypothesized that, similar to Hh signaling, late Gli1 induction by TGF-β may be dependent on early Gli2 activation. Consistent with this hypothesis, Gli2 knockdown with Gli2 siRNAs, which efficiently abrogated Gli2 induction by TGF-β ( Fig. 3E, right 
Pharmacologic inhibition of TGF-β β β β signaling inhibits the growth of cyclopamineresistant pancreatic adenocarcinoma cell lines:
There is ample evidence that Gli genes possess activities that are independent from Hh signaling. For example, Gli2 and Gli3 are widely expressed in the developing embryo, including in regions that are far from Shh production (32) , and may be expressed downstream of FGF signaling (33) . Also, mice expressing mutant forms of Gli2 or Gli3 exhibit defects that are likely not solely dependent on loss of Hh signaling (34) . Thus, what is crucial for a given cell is the overall state of Gli expression and function, and Hh might just be one of several ways to regulate it (2) . In this context, a growing number of reports indicates the potential therapeutic benefit of targeting either the TGF-β/Smad or Shh/Gli signaling pathways to counter the neoplastic process, consistent with their respective pro-oncogenic capacities. For example, cyclopamine and small-molecule Shh antagonists have shown efficacy in reducing tumor burden and inducing cancer cell apoptosis (13, 35, 36) . Likewise, interfering with TGF-β signaling has shown promising results in preventing tumor development in a variety of tumor types (37-42). To identify specific molecular signatures in a given tumor is critical to help determine the adequate therapeutic strategy (43). Interestingly, in a study involving numerous pancreatic carcinoma cell lines, inhibition of the Hh pathway by cyclopamine led to reduced proliferation and increased apoptosis only in a subset of cells. On the other hand, the authors identified another subset of cancer cells that was entirely resistant to cyclopamine, suggesting that their constitutive Hh activation, estimated as Gli1 or Ptch-1 expression, may not occur via Ptch/Smo (13) . We thus tested the possibility that TGF-β/Smad signaling may contribute to constitutive Gli expression in the cyclopamine resistant PANC-1 cell line (13) , and whether pharmacologic inhibition of the TGF-β pathway may inhibit their proliferation. As shown in Fig. 5A , PANC-1 cells showed significantly impaired growth when treated with the TβRI/ALK5 inhibitor SB431542, not with cyclopamine, accompanied with decreased basal
Gli2 expression, as measured by quantitative RT-PCR ( Fig. 5B ), suggesting that autocrine TGF-β signaling may contribute to basal Gli2 expression. Similar results were obtained with the BxPC-3 cell line (not shown). Transfection of PANC-1 cells with Gli2 siRNA efficiently reduced basal Gli1 expression ( Fig. 5C ), PANC-1 cell growth (Fig. 5D ), and strongly attenuated the anti-proliferative effect of SB431542 (Fig. 5D ). Together, these data indicate that the growth inhibitory activity of SB431542 on PANC-1 cells is, at least in part, driven by a reduction in Gli expression.
Conclusion:
We have identified TGF-β as a potent inducer of both Gli1 and Gli2 expression, 
